<!DOCTYPE html>
<html lang="en-US"><head>
		<meta charset="UTF-8">
		<title>FR940912-2-00080</title>
	</head>
	<body>
		<main>
			<p><!-- PJG STAG 4703 -->  <!-- PJG ITAG l=84 g=1 f=1 --> Appendix I <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=21 g=1 f=1 --> In the Matter of: Roche Holding Ltd, a corporation, and Syntex Corporation, a corporation; agreement to hold separate. <!-- PJG /ITAG -->  <!-- PJG QTAG 04 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline -->  <!-- PJG ITAG l=11 g=1 f=1 --> This Agreement to Hold Separate (``Hold Separate'') is by and between Roche Holding Ltd (``Roche''), a corporation organized, existing, and doing business under and by virtue of the laws of Switzerland, with its office and principal place of business at Grenzacherstrasse 124, Basel, Switzerland 4002; Syntex Corporation (``Syntex''), a corporation, organized, existing, and doing business under and by virtue of the laws of Panama with its principal place of business located at 3401 Hillview Avenue, Palo Alto, California 94304; and the Federal Trade Commission (``the Commission''), an independent agency of the United States Government, established under the Federal Trade Commission Act of 1914, 15 U.S.C. section 41,  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> et seq.  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> (collectively, the ``Parties''). <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=84 g=1 f=1 --> Premises <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> Whereas, on May 1, 1994, Roche entered into an Acquisition Agreement and Plan of Merger with Syntex Corporation (``Syntex'') to acquire all the voting stock of Syntex (hereinafter ``Acquisition''); and <!-- PJG 0012 frnewline --> Whereas, Syntex with its principal office and place of business located at 3401 Hillview Avenue, Palo Alto, California 94304, manufacturers and markets through its indirect wholly-owned subsidiary, the Syva Company, among other things, drugs of abuse reagent products; and <!-- PJG 0012 frnewline --> Whereas, Hoffmann-La Roche Inc., an indirect wholly-owned subsidiary of Roche, with its principal office and place of business located at 340 Kingsland Street, Nutley, New Jersey 07110, through its subsidiary Roche Diagnostic Systems, Inc., manufacturers and markets, among other things, drugs of abuse reagent products; and <!-- PJG 0012 frnewline --> Whereas, the Commission is now investigating the Acquisition to determine whether it would violate any of the statutes enforced by the Commission; and <!-- PJG 0012 frnewline --> Whereas, if the Commission accepts the Agreement Containing Consent Order (``Consent Order''), the Commission must place it on the public record for a period of at least sixty (60) days and may subsequently withdraw such acceptance pursuant to the provisions of &sect;2.34 of the Commission's Rules; and  <!-- PJG 0012 frnewline --> Whereas, the Commission is concerned that if an understanding is not reached, preserving the status quo ante of the Syva Business as defined in paragraph I. of the Consent Order during the period prior to the final acceptance of the Consent Order by the Commission (after the 60-day public comment period), divestiture resulting from any proceeding challenging the legality of the Acquisition might not be possible, or might be less than an effective remedy; and <!-- PJG 0012 frnewline --> Whereas, the Commission is concerned that if the Acquisition is consummated, it will be necessary to preserve the Commission's ability to require the divestiture of the Syva Business and the Commission's right to have the Syva Business continue as a viable competitor; and <!-- PJG 0012 frnewline --> Whereas, the purpose of the Hold Separate and the Consent Order is: <!-- PJG 0012 frnewline --> 1. to preserve the Syva Business as a viable, independent business pending its divestiture as a viable and ongoing enterprise, <!-- PJG 0012 frnewline --> 2. to remedy any anticompetitive effects of the Acquisition, and <!-- PJG 0012 frnewline --> 3. to preserve the Syva Business as an ongoing and competitive entity engaged in the same business in which it is presently employed until divestiture is achieved; and  <!-- PJG /ITAG -->  <!-- PJG /STAG --></p>
		</main>
</body></html>
            